Limb cryocompression to prevent chemotherapy-related nerve damage
Official title: A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study
Run by National University Hospital, Singapore · NCT05606068 · Data updated 2026-11-12
We will test whether cooling your arms and legs with the Paxman Limb Cryocompression System can prevent nerve damage in people with cancer receiving weekly paclitaxel chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | National University Hospital, Singapore Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Singapore and 1 other locations) |
| Status | Recruiting |
| Started | November 11, 2022 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT05606068 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 21–80 who are scheduled to receive weekly paclitaxel, have a baseline Total Neuropathy Score of 5 or less, and do not have open limb wounds, Raynaud's, peripheral vascular disease, poorly controlled diabetes, or pregnancy.
✕Probably not a fit
Patients with open limb wounds, significant vascular disease or Raynaud's, poorly controlled diabetes, pregnancy, or baseline neuropathy above the study cutoff are unlikely to benefit or are excluded from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This expansion study will enroll about 80 cancer patients at centers in Singapore to test repeated limb cryocompression over multiple cycles of weekly paclitaxel. Using the Paxman Limb Cryocompression System, cooling wraps will be applied from the digits to the elbow or knee at an established optimal temperature and pressure during chemotherapy infusions. Patients will be monitored for safety and signs of peripheral neuropathy over the treatment course. Key exclusions include open limb wounds, Raynaud's phenomenon, peripheral vascular disease, poorly controlled diabetes, pregnancy, and baseline neuropathy above the study cutoff.
Why it matters
Potential benefit: If successful, this could reduce or prevent painful numbness and tingling in the hands and feet caused by taxane chemotherapy, helping patients preserve sensation and function.
How similar studies have gone: Previous small trials and case series of limb cooling or cryocompression for preventing chemotherapy-induced neuropathy have shown promising results, but larger randomized data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 21- 80 years. * Signed informed consent from patient or legal representative * Scheduled to receive weekly paclitaxel chemotherapy * Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum/Herceptin. Exclusion Criteria: * Open skin wound or ulcers of the limbs * History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes * Pregnant woman * A score of more than 5 in Total Neuropathy Score (TNS) at baseline for cancer patients
Where it's running
-
National University Hospital
Singapore, Singapore Recruiting -
Curie Oncology, Mount Elizabeth Novena Specialist Centre
Singapore, Singapore Not yet recruiting
Study contacts
- Principal investigator: Rachel Wong — National University Hospital, Singapore
- Study coordinator: Rachel Wong
- Email: rachel_sj_wong@nuhs.edu.sg
- Phone: 6908 2222
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cryotherapy during weekly paclitaxel to reduce chemotherapy-induced numbness and tingling
This study tests whether applying cryotherapy to hands and feet during weekly paclitaxel helps prevent CIPN in women with breast cancer.
-
SIR2501 plus Paclitaxel for solid tumors
This Phase 2 study tests SIR2501 in adults with solid tumors who are starting paclitaxel chemotherapy to see if it is safe and tolerable and to explore its effect on chemotherapy-induced neuropathy.
-
Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors
This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.
-
Self-applied ear vagus nerve stimulation for chemotherapy-induced neuropathy
Researchers are testing a small, at-home device that you wear on the ear to see if it eases nerve pain from chemotherapy.
-
Blood extracellular vesicles to detect chemotherapy-related nerve damage.
We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.
-
Virtual LASO-3 diet program to ease chemotherapy-related numbness and tingling
This trial tests whether a virtual diet program that lowers added sugar and increases fiber and omega-3s can help cancer survivors who have numbness, tingling, or pain after neurotoxic chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.